Valuation: Golden Biotechnology Corporation

Capitalization 2.15B 73.55M 62.89M 58.58M 54.49M 101M 6.31B 112M 702M 268M 2.95B 276M 270M 10.84B P/E ratio 2023
-15.4x
P/E ratio 2024 -6.49x
Enterprise value 2.3B 78.63M 67.24M 62.63M 58.25M 108M 6.75B 120M 750M 287M 3.16B 295M 289M 11.59B EV / Sales 2023
89x
EV / Sales 2024 65.3x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2024 Apr. 25 CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2024 24-08-11 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 24-04-29 CI
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol 24-01-18 CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 23-08-13 CI
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer 23-05-05 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 23-04-28 CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022 22-08-11 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 22-04-27 CI
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients 22-01-07 CI
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients 21-09-16 CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021 21-08-15 CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 21-03-30 CI
More news
1 day-0.75%
1 week-2.21%
Current month+9.96%
1 month+3.11%
3 months+2.32%
6 months-30.08%
Current year-14.79%
More quotes
1 week 12.45
Extreme 12.45
14.05
1 month 11.5
Extreme 11.5
14.05
Current year 11.35
Extreme 11.35
19.6
1 year 11.35
Extreme 11.35
22.75
3 years 11.35
Extreme 11.35
135
5 years 11.35
Extreme 11.35
335
10 years 11.35
Extreme 11.35
335
More quotes
Manager TitleAgeSince
President 70 2002-09-26
Chief Tech/Sci/R&D Officer - 2016-07-31
Chief Tech/Sci/R&D Officer - 2006-07-31
Director TitleAgeSince
Chairman 63 2002-09-26
Director/Board Member 50 2009-06-25
Director/Board Member 70 2002-09-26
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.75%-2.21%-39.91%-89.09% 73.55M
-1.01%+2.87%+11.41%+37.60% 34.39B
+9.99%+8.94%+98.84%-27.08% 30.84B
-0.90%+2.63%+32.89%-30.06% 27.8B
+1.57%+0.39%+27.99%+328.17% 18.65B
-3.40%+1.83%+192.40%+2,613.85% 18.57B
+3.70%+1.72%+132.55%-64.40% 13.81B
-1.18%+6.12%-25.33%-43.89% 13.28B
+4.52%-2.50%+181.59%+419.27% 12.94B
-0.69%-2.80%+100.27%+112.91% 12.23B
Average +1.19%+2.74%+71.27%+325.73% 18.26B
Weighted average by Cap. +1.64%+4.27%+74.03%+326.42%
See all sector performances

Financials

2023 2024
Net sales 63.43M 2.17M 1.86M 1.73M 1.61M 2.97M 186M 3.3M 20.71M 7.92M 87.19M 8.14M 7.97M 320M 40.92M 1.4M 1.2M 1.12M 1.04M 1.92M 120M 2.13M 13.36M 5.11M 56.25M 5.25M 5.14M 206M
Net income -362M -12.37M -10.58M -9.86M -9.17M -16.94M -1.06B -18.82M -118M -45.15M -497M -46.41M -45.45M -1.82B -361M -12.34M -10.55M -9.83M -9.14M -16.89M -1.06B -18.77M -118M -45.03M -496M -46.29M -45.33M -1.82B
Net Debt 61.04M 2.09M 1.79M 1.66M 1.55M 2.86M 179M 3.18M 19.93M 7.62M 83.91M 7.83M 7.67M 308M 149M 5.08M 4.35M 4.05M 3.76M 6.96M 436M 7.73M 48.5M 18.54M 204M 19.06M 18.66M 749M
More financial data * Estimated data
Logo Golden Biotechnology Corporation
Golden Biotechnology Corp is a Taiwan-based company mainly engaged in the development of new anti-cancer drugs. The Company's main development projects are novel compounds of Antroquinonol for the treatment of non-small cell lung cancer, acute myeloid leukemia, pancreatic cancer, hyperlipidemia, hepatitis B, and Corona Virus Disease 2019 (Covid-19), which are broadly effective small molecule drugs with no systemic toxicity. The Company is also engaged in the manufacture and sales of health foods and dietary supplements. The main products include antrodia camphorata mycelium capsules and others. The Company sells products in the Taiwan market as well as in other areas of Asia.
Employees
122
More about the company
Date Price Change Volume
25-07-11 13.25 NT$ -0.75% 94,127
25-07-10 13.35 NT$ +1.14% 376,009
25-07-09 13.20 NT$ -1.49% 181,810
25-07-08 13.40 NT$ -1.11% 430,094
25-07-07 13.55 NT$ 0.00% 526,338

End-of-day quote Taipei Exchange, July 10, 2025

More quotes